FDA has ordered specialty pharmacies and online companies to phase out knockoff versions of Eli Lilly blockbuster drugs ...

It’s been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling.

Hims recaps the year's most surprising health findings, from the growing number of adults who consider monogamy optional to ...

The Short discusses a 15% drop in Hims & Hers stock following an FDA announcement ending the shortage of Eli Lilly's weight ...

Craig Hettenbach, an analyst from Morgan Stanley, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated ...

Hims & Hers is transforming telehealth with personalized medications, rapid subscription growth, and strong financials, ...

Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and ...

Hims & Hers stock price has greatly performed this year as it continued to disrupt the healthcare industry. HIMS has jumped ...

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

Hims & Hers Health Inc (HIMS) stock saw a decline, ending the day at $26.36 which represents a decrease of $-2.19 or -7.67% from the prior close of $28.55. The stock opened at $26.04 and touched a low ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

Analyst Allen Lutz of Bank of America Securities maintained a Sell rating on Hims & Hers Health (HIMS – Research Report), retaining the ...